Aroa’s Symphony in sweet spot from US insurer reset
The ASX-listed Kiwi company has set an ambitious FY27 target with growth from its Myriad and Symphony product lines.
Aroa’s products stem from its Extracellular Matrix (ECM) biotechnology platform, which is derived from sheep forestomach.
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
ASX-listed and New Zealand-based medical technology company Aroa Biosurgery has set an ambitious FY27 revenue forecast that includes the start of what could be a big opportunity from outpatient wound care.
Aroa makes, sells, and distributes a range of medical and surgical products to improve
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Subscribe Now
Monthly Premium Online Subscription
NZ$49.95 / monthly
Subscribe Now
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Subscribe Now
Yearly Premium Online Subscription
NZ$499.00 / yearly
Subscribe Now
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly
credit card debit
Subscribe Now
Premium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly
credit card debit
Subscribe Now
Yearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Subscribe Now
Individual
Group membership
NBR Marketplace
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
